🇺🇸

Index Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — March 06, 2026

Across 110 SEC filings from diverse US-listed firms (despite DJIA 30 focus, spanning banks, biotechs, SPACs, energy, and fintech), sentiment is predominantly mixed/neutral (70+ filings), with 25% positive on growth catalysts like revenue surges (avg +20-30% YoY in standouts like Grab, Via, Republic Bancorp) and clinical progress, but offset by cash burns, impairments, and exec churn. Period-over-period trends reveal banking sector resilience (e.g., NIM expansions in Republic +20bps, Northrim +NII 20%) amid rising NPLs (e.g., Home Bancorp 1.25% vs 0.50%), while biotechs show widened losses (PMV +32% YoY) but pipeline advances; energy firms mixed with Mammoth liquidity up to $158M post-divestitures. Capital allocation leans conservative (shelf registrations, buybacks like Dave $70M repurchase, Harley 10b5-1 plan), with SPACs/M&A active (ReserveOne, Vine Hill). Forward-looking catalysts cluster in Q1-Q2 2026 (PMV NDA, Nuvve BESS ops, Aptiv spin-off), signaling near-term volatility but alpha in undervalued growth names. Portfolio implication: Rotate to banks with NIM tailwinds and biotechs with derisked trials, hedge delisting/Nasdaq risks in small caps.

75 high priority 35 medium 110 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 06, 2026

Across 85 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, automotive, hospitality, and adjacent sectors), overarching themes include mixed financial performance with 12/25 10-Ks showing YoY revenue growth averaging +18% (e.g., Chime +31%, Guidewire +25%) offset by declines in 8/25 averaging -15% (e.g., MarketWise -19.7%, Oxford Square portfolio -3.4%), margin compression in 10/20 reporting cos averaging -100bps amid expense growth, and robust capital returns via dividends (15 declarations, avg +10%) and buybacks (5 programs expanded/resumed). Critical developments feature accretive M&A (Chatham Lodging hotels at 10% cap rate adding 12% EBITDA, Kratos/Orbit $353M), spin-offs (Aptiv/Versigent by Apr 2026 with $1.7B dividend), and guidance raises (MarketWise FY26 billings to $300M, CFFO $50M). Portfolio-level patterns reveal hospitality strength (RevPAR +15% in acquisitions), subscription shifts to higher-ARPU (MarketWise ARPU $670), and bank-like efficiency gains (NII +15% avg in financial adjacents), signaling resilience in consumer spending pockets but caution on costs/delisting risks. Forward catalysts cluster in Apr-May 2026 (proxies, dividends, deal closes), positioning selective buys in undervalued growth names.

60 high priority 25 medium 85 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 06, 2026

Across 38 filings in the USA S&P 500 Healthcare intelligence stream (including tangential financials, biotechs, and providers), mixed sentiment dominates (15/38 filings), reflecting revenue/NII growth (avg 20% YoY in banks like Arrow +19.2%, Chime +31%) offset by rising expenses/losses (Chime net loss x40 to $1.01B, Jade +171% YoY) and asset quality slips (Flushing NPAs +25% YoY). Biotech standouts like Solid Biosciences ($240M raise, runway H1 2028), Jade ($336M cash post-$180M PIPE, Phase 1/2 data Q2 2026), and Absci (new CMO) signal pipeline conviction amid R&D surges. Healthcare provider Humana gears up for Apr 16 AGM with refreshed board (9/10 independent, age 73 retirement policy). Capital allocation shines with buyback expansions (Lakeland to $60M, Guidewire $148M repurchased), dividends (Broadridge $0.975/share), splits (HBIO 1:10 effective Mar 13), and financings (Core Scientific $500M loan to $1B accordion). Portfolio trends show NIM expansion (~+40bps avg in 7 banks to 3.6%), but NPAs rising in 4/6 banks (avg +18% YoY); April AGM cluster as key catalyst for governance votes. Implications: Favor growth biotechs/banks with strong liquidity, trim deteriorating asset quality names ahead of meetings.

27 high priority 11 medium 38 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 05, 2026

Across 50 filings from the S&P 500 Consumer Staples stream and adjacent sectors, sentiment is predominantly mixed (18/50 filings), reflecting resilient top-line growth in staples/wholesale leaders like Costco (+9.1% YoY Q2 sales, +7.4% comps) and BJ's (+4.6% FY sales, +9.5% membership fees) offset by softness elsewhere (Kroger FY sales flat YoY, Clarus FY sales -5.3% YoY). Period-over-period trends show average revenue growth of ~+5% YoY in reporting consumer firms (e.g., 6/12 with sales data >+4% YoY) but margin compression in 7/12 (avg -100 bps, e.g., Clarus gross margin -190 bps, Kroger OG&A +29 bps FY), impairments rampant (10+ filings, e.g., Kroger $2.5B, Lineage $14.8M), and narrowing losses in turnarounds (flyExclusive net loss -34% YoY). Capital allocation tilts shareholder-friendly with buybacks (Kroger $7.5B completed +$2B approved, BJ's $117.7M Q4) and dividend hikes (Philip Morris to $1.47, Korn Ferry +14.6% to $0.55), while financing ramps for liquidity (Pulmonx $60M facility, Vivakor $750k note amid distress). Forward-looking signals mixed: upbeat guidance (Clarus 2026 sales +2-6% YoY, EBITDA to $9-11M), but narrows (Methode FY26 sales $950M-1B). Portfolio-level: staples show defensive comp sales (+1-7% YoY avg), but broader distress in non-core (Monroe Capital NII -53% YoY). Critical implications: favor wholesale staples for stability, monitor impairments/debt for staples-adjacent risks.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 05, 2026

Across 92 SEC filings from the USA S&P 500 Industrials intelligence stream (including energy services, transportation, machinery, and adjacent sectors like aerospace/defense), mixed sentiment prevails in 70% of cases, reflecting revenue growth in production-heavy firms (avg +15% YoY in energy/oil like Granite Ridge +27%, SandRidge +12%) offset by service declines (Ranger Energy -4% FY revenue) and margin compression (avg -50 bps where reported). Period-over-period trends show improving net losses in 40% of biotechs/pharmas (e.g., Gevo -57%, Lexicon -75%) but widening in others (EyePoint +77%), with capital allocation favoring dividends/buybacks (Kroger $7.5B repurchases, Ranger $42.9M FCF to returns >40%). M&A/SPAC activity surges (Pasqal $2B Bleichroeder merger H2 2026, Home Bancshares MCBI Q2 2026), alongside leadership churn in transportation (Delta exec promotions). Forward-looking guidance clusters around modest 2026 growth (Granite Ridge +9%, Traeger flat revenues), building a catalyst calendar heavy in Q2 trial data/FDA meetings. Portfolio-level, Industrials exhibit resilient production amid pricing pressures, signaling selective upside in energy services/transport but risks from impairments/debt.

55 high priority 37 medium 92 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 05, 2026

The sole filing in the USA S&P 500 Energy intelligence stream is an 8-K from Copper Property CTL Pass Through Trust, announcing a monthly cash distribution of $0.082844 per trust certificate, payable on March 10, 2026, to holders of record on March 9, 2026. This reflects positive sentiment (rated positive) and steady capital allocation focused on shareholder returns via distributions, with materiality at 6/10. No period-over-period comparisons, YoY/QoQ trends, insider trading activity, forward-looking guidance, M&A details, financial ratios, or operational metrics were disclosed in the filing, limiting quantitative trend analysis across the sector. The availability of the monthly report for the period ending February 28, 2026, on the investor website (www.ctltrust.net) enhances transparency. Key implication: This signals reliable income generation in the energy sector trust space, potentially appealing to yield-seeking investors amid stable cash flows, though absence of comparative data prevents identifying growth or margin trends at a portfolio level.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 05, 2026

Across the 416 pre-analyzed SEC filings from S&P 500 Financials and adjacent sectors (though data skews to energy, biotech, retail, and industrials), overarching themes include mixed FY2025 results with revenue growth in 62% of reporting companies (avg +12% YoY) offset by margin compression in 58% (avg -85 bps YoY), driven by higher operating costs and impairments; capital allocation favors buybacks/dividends in 28 companies (e.g., $7.5B Kroger repurchase completed, $2B authorized). Insider activity shows neutral conviction with appointments dominant (e.g., 15 new directors/CFOs) but few buys/sells. Forward-looking guidance is cautious with 45% raising revenue targets (avg +10%) but 32% trimming EBITDA/margins amid economic pressures. M&A accelerates (12 deals, avg $500M+ valuation, e.g., USA Rare Earth $73M acquisition), signaling consolidation. Portfolio-level trends: EBITDA flat/declining in 55% despite revenue beats, highlighting cost inflation; energy/biotech outliers with 20-50% YoY declines in key metrics. Implications: Favor resilient dividend payers and M&A targets; avoid margin squeezes in retail/energy.

227 high priority 189 medium 416 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 05, 2026

Across 20 SEC filings from diverse sectors mislabeled under S&P 500 Technology stream, dominant themes include robust revenue growth in 9/20 companies (avg +35% YoY where quantified, e.g., Evommune +86%, Entravision +23%, CrowdStrike +22%) offset by widening net losses in 10/20 (e.g., CrowdStrike loss to $162.5M, Entravision to $79.2M) due to surging OpEx (avg +25% YoY). Mixed sentiment prevails (12/20 filings), with positive catalysts like biotech trials (Altimmune Q3 2026 RECLAIM data, Evommune 2Q/2H26 Phase 2b), capital allocation via dividends (Iridium $0.15/share, Entravision $0.20), M&A/divestitures (CYH $112M hospital sale Q2 2026 close, Genco vessel acquisition), and restructurings (Cumulus prepackaged Ch.11). Margin compressions hit 7/15 with data (avg -100bps, e.g., NCS services to 45%, Weave onboarding -153%), while cash positions strengthened in biotechs (Altimmune +107% YoY to $274M, Evommune to $216.7M). Insider activity limited to appointments (Acadia new director, Altimmune CEO change), no major buys/sells. Portfolio implications: Bullish on turnaround growth (Adial loss -40% YoY), bearish on bankruptcy risks (Cumulus); monitor Q2 2026 catalysts for alpha in undervalued assets.

14 high priority 6 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 05, 2026

Across 22 NASDAQ-100 filings, mixed sentiment prevails with 12/15 annual reports showing average revenue growth of 25% YoY (range +9% Costco to +86% Evommune) driven by tech/services/advertising segments, but offset by profitability pressures including widened losses (e.g., +3% Evommune, +12% Metagenomi), impairments (Entravision $55M), and margin declines (NCS services 45% vs 49%). Biotech cluster (Altimmune, Evommune, Metagenomi, Adial) highlights pipeline catalysts and cash runways to 2027-28 despite revenue volatility (-52% Metagenomi). Media/comms face headwinds (Cumulus bankruptcy prep, Entravision media -20-32% YoY), while retail (Costco +9% sales) and shipping (Genco acquisition) shine. Capital allocation steady with dividends (Iridium $0.15, Entravision $0.20 unchanged), reverse split (Aditxt 1:8), and M&A (CYH $112M sale Q2 2026). Portfolio implications: Favor consumer/biotech catalysts, avoid distressed media, monitor restructuring votes/debt closes for near-term volatility.

15 high priority 7 medium 22 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 05, 2026

Across 118 SEC filings from the USA Dow Jones 30 intelligence stream (covering diverse sectors but focused on blue-chips and related), overarching themes include resilient YoY revenue growth averaging +15% in 35/118 companies (e.g., Grid Dynamics +17.5%, CrowdStrike +22%, Hippo +26%) offset by widespread margin compression (-100 to -200 bps in 28 firms like OLAPLEX -27.6% Adj EBITDA drop) and mixed sentiment (62% mixed, 18% positive). Period-over-period trends show QoQ improvements in Q4 for 22 companies (e.g., Ranger Energy revenue +10% QoQ) but FY losses widening in tech/services (CrowdStrike net loss -$162.5M vs -$15.2M prior). Capital allocation remains shareholder-friendly with buybacks/dividends in 15 filings (e.g., BJ's $117.7M Q4 repurchases, Ranger 994k shares), while forward guidance signals caution (e.g., OLAPLEX FY26 sales flat, Grove revenue decline). M&A/divestitures active (Six Flags $331M parks sale, Aptiv spin-off), and insider conviction mixed with no major sales but leadership changes (Trulieve CAO termination). Portfolio implications: Favor margin-resilient growers like Invivyd (revenue doubled) over compressors; monitor energy transition plays (Greenidge AI/HPC shift). Critical developments: AI-driven growth (Grid Dynamics AI 25% of Q4) vs expense surges, positioning selective longs in tech/finance amid macro softness.

70 high priority 48 medium 118 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 05, 2026

Across 71 SEC filings from diverse sectors mislabeled under S&P 500 Consumer Discretionary (including energy, financials, tech, and true disc like entertainment), overarching themes include robust revenue/production growth averaging 20-50% YoY in 25+ companies (e.g., Granite Ridge +27% prod, FTC Solar +149% Q4 rev, Profound Medical +50%), tempered by persistent net losses or margin compression in 30+ firms due to higher opex/LOE (e.g., flyExclusive retail -39% Q4, Mobile Infra rev -5%). Capital allocation shines with aggressive buybacks (Zillow +$1.25B to $1.3B capacity, Paycom +$200M) and dividend hikes (Korn Ferry +14.6% to $0.55), signaling management conviction amid mixed sentiment (45/71 mixed/neutral). Forward-looking data reveals optimistic 2026 guidances in energy/tech (SandRidge 6.4-7.7 MMBoe, Bridger $135-145M rev, TriSalus $60-62M), spin-offs (Aptiv Versigent April 1), and divestitures (Six Flags $331M parks sale). Portfolio-level trends show outperformance in production/reserves growth (energy avg +15-28% YoY) vs deteriorating retail/consumer metrics (flyExclusive fractional retail -8% YTD, NIKE $300M restructuring charges). Critical implications: prioritize capital return plays and guided growth; avoid prolonged loss-makers like Research Frontiers (cash -67%).

32 high priority 39 medium 71 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 05, 2026

Across 31 SEC filings from the USA S&P 500 Healthcare stream (with broader S&P exposure), overarching themes include robust revenue growth in healthcare/biotech (e.g., TriSalus 53% YoY to $45.2M, Caribou 12% to $11.2M) and select financials (South Plains 13.6% NII growth), offset by pervasive margin compression (TriSalus GM -150bps to 84.6%, Ciena -20bps to 43.8%) and widening net losses (TriSalus -30.6% to $39.2M, Caribou flat at $148M amid impairments). Mixed sentiment dominates (14/20 detailed), driven by top-line beats/guidance reaffirms (TriSalus exceeded FY25, reaffirms 2026 $60-62M) but elevated costs/op-ex (S&M/G&A up double-digits across biotech) and litigation costs (Moderna $950M settlement). Capital allocation favors buybacks (Ciena $80.5M, News Corp $1B program) and dividends (NewLake Q1 2026 $0.43/share), with healthcare firms pursuing M&A/raises (TriSalus $46M offering, Moderna royalty-free license). Portfolio-level trends show 7/12 revenue reporters >20% YoY growth but 6/8 with op loss expansion; proxy season ramps with 8 Apr 2026 meetings signaling comp votes amid strong TSR (BNY 178%, First Business 235%). Critical developments: litigation resolutions (Moderna) and board enhancements (PacBio AI expert) provide catalysts, implying selective healthcare upside amid financial stability.

17 high priority 14 medium 31 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 04, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (broadly including food, beverages, household, and adjacent sectors), overarching themes include heightened governance activity with 12+ proxy statements (DEF 14A/DEFA14A) signaling board refreshes, annual meetings, and shareholder proposals, alongside mixed financial results showing revenue growth in 6/20 reporting companies (avg +30% YoY outliers like Kontoor +21%, Bankwell +25% total revenue) but declines in 7/20 (avg -8% YoY, e.g., Cracker Barrel -7.9%). Margin trends are bifurcated: expansions in 5 companies (ImmuCell +1140bps to 41.4%, Pulmonx Q4 +400bps to 78%) versus compressions in 4 (Kontoor op margin -240bps to 10.7%). Capital allocation leans defensive with steady dividends (Horizon $0.06/month, Helmerich $0.25/quarter) and buybacks (Kontoor repurchased at $67.58 avg), while divestitures (Hain Celestial Snacks sale) and M&A progress (Horizon-Monroe merger) aim to deleverage. Forward-looking catalysts cluster in Q2 2026 (10+ AGMs April-May) and biotech milestones (Cellectar EMA Q3 2026), but cash burns (Cellectar -43% YoY) and net losses (12/25 firms) flag funding risks. Portfolio-level, neutral-mixed sentiment (60% mixed/neutral) implies sector resilience amid consumer pressures, favoring dividend payers and turnaround plays.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 04, 2026

Across 69 SEC filings from S&P 500 Industrials and related sectors, dominant themes include mixed financial results with revenue growth in 12/20 key earners (avg +15% YoY, e.g., Black Rock Coffee +24.5%, CPS Technologies +54%) offset by widespread margin compression (avg -150 bps in 8/15 reporters) and net loss expansions (e.g., Ocugen +25%, Rigetti +8%). Biotech and tech firms highlight clinical catalysts (e.g., Ocugen OCU410ST interim Q3 2026, EyePoint DURAVYU topline mid-2026) amid cash burn concerns, while industrials like Babcock & Wilcox show backlog surges (+470% YoY). SPAC activity intensifies with extensions (Goldenstone to Dec 2026) and mergers (Bleichroeder-Pasqal $2B valuation), signaling M&A momentum. Capital allocation leans toward buybacks/dividends (Abercrombie $450M repurchase, Bath & Body $400M) but dilutions via equity raises dilute shareholders (Regen BioPharma +77M shares). Portfolio-level trends flag deteriorating profitability despite top-line resilience, with forward guidance cautious (e.g., Cracker Barrel revenue -2.5-4.5% FY2026). Actionable implications: Favor backlog-rich industrials, monitor biotech catalysts, avoid high-dilution names.

34 high priority 35 medium 69 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 04, 2026

Across the four filings in the S&P 500 Energy stream, Hess Midstream LP dominates with positive capital allocation via a $60M accretive repurchase program, signaling strong management conviction and commitment to 5% annual distribution growth through 2028 while preserving $1B in flexibility. Real Brokerage Inc. highlights a pristine balance sheet with zero long-term debt, leases, or liabilities, and 210.5M shares outstanding, underscoring financial stability amid no ICFR changes. BRT Apartments Corp. reports a smooth CFO transition with vesting of 42,800 restricted shares but forfeiture of RSUs, maintaining neutral sentiment. A Paradise Acquisition Corp.'s SPAC pursuit of Enhanced Ltd. reveals mixed sentiment due to high risks like regulatory scrutiny and minimal revenue, contrasting sector peers. No uniform period-over-period trends emerge as filings lack comprehensive financial comparisons, but capital returns and low-debt profiles point to defensive positioning. Key implication: Energy midstream shows shareholder-friendly actions amid limited sector catalysts on March 4, 2026.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 04, 2026

Across 365 SEC filings from diverse S&P 500 Financials-adjacent sectors (including banks, insurers, healthcare, energy, retail), overarching themes include robust YoY revenue growth averaging +15% in high-materiality filings (e.g., National Vision +9% FY, Viemed +21% FY, BillionToOne +100% FY), but widespread margin compression (-100 to -200 bps YoY in 12/20 key reports like Gran Tierra -37% netback, Grocery Outlet impairments) and mixed profitability with 40% reporting net losses or widened deficits. Capital allocation trends favor shareholder returns (buybacks in 15 filings totaling $500M+, dividends steady/growing in 10 like Horizon $0.18/share Q2), while M&A/refinancings (e.g., Cooper-Standard debt swap, SSR Mining $1.5B asset sale) signal deleveraging. Insider activity sparse but positive conviction in repurchases; forward guidance optimistic for 2026 (revenue +10-40% in 20 filings). Portfolio-level: Healthcare/biotech shows pipeline catalysts (Ocugen Phase 3 topline Q1 2027) offsetting cash burn; energy mixed on production vs. prices; retail impairments flag caution. Actionable: Favor growth names with raised guidance amid macro volatility.

193 high priority 172 medium 365 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 04, 2026

Across the 8 filings in the USA S&P 500 Technology intelligence stream, proxy season kicks off prominently with Texas Instruments (TXN) DEF 14A and DEFA14A filings highlighting the April 16, 2026 annual meeting, alongside neutral Nuveen fund proxies, signaling routine governance but no major shifts. Broadcom Inc. dominates with blockbuster Q1 FY2026 results: revenue +29% YoY to $19.3B, AI revenue exploding +106% YoY to $8.4B, and Q2 guidance of $22B (+47% YoY), underscoring semiconductor/AI strength amid sector volatility. ImmuCell shows modest recovery with 2025 sales +4.3% YoY to $27.6M and gross margins expanding +1,140bps to 41.4%, though offset by one-time charges leading to net loss; Nuveen Quality Municipal's VRDP redemption extension to 2056 is a liquidity win. Other filings like NCS Multistage and AParadise SPAC reveal sparse data and high risks, respectively. Portfolio-level trends show YoY revenue acceleration in semis (Broadcom outlier at +29%) vs modest growth elsewhere, with capital returns via Broadcom's new $10B buyback and dividend. Mixed sentiment prevails (3/8 mixed), but AI-driven semis signal outperformance potential amid proxy governance focus.

3 high priority 5 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 04, 2026

Across 14 NASDAQ-100 related SEC filings from March 4, 2026, dominant themes include robust semiconductor growth led by Broadcom's 29% YoY revenue surge and 106% AI acceleration, contrasted by mixed biotech results with PepGen narrowing losses but facing FDA holds and ImmuCell achieving 41.4% gross margins (up from 30%) despite net losses from write-downs. Proxy season kicks off with TXN and Nuveen funds scheduling April 16 meetings, signaling governance focus amid stable capital structures like NAD's VRDP redemption extension to 2056. Shipping (Costamare) shows long-term charter stability with TEU-weighted durations up to 6.9 years, while SPACs (AParadise) highlight high-risk combinations. Portfolio-level trends reveal 3/5 companies with revenue growth averaging 27% YoY (Broadcom, ImmuCell, AITX implied), margin expansions in ops-heavy firms (+1,140bps for ImmuCell), but persistent net losses in biotechs (PepGen -4% YoY op ex decline). Capital returns shine via Broadcom's $10B buyback and dividend, positioning AI/semicon as outperformers vs. biotech underperformers on cash burn. Implications favor rotating into semis/AI catalysts while monitoring biotech clinical risks and proxy outcomes for governance shifts.

6 high priority 8 medium 14 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 04, 2026

Across 121 SEC filings from diverse US companies (despite DJ30 focus, spanning retail, healthcare, energy, tech, and industrials), overarching themes include mixed financial results with 22/45 quantifiable revenue reporters showing YoY growth averaging +15% (e.g., Republic Airways +20.6%, Veeva +16%), but 12 experiencing declines averaging -8% (e.g., Cracker Barrel -7.9%, Bath & Body Works -2%), driven by margin compression in retail (-150bps avg in 5 cos) and consumer weakness offset by M&A-fueled gains. Capital allocation leans bullish with 9 share repurchase programs (e.g., Innovative $100M, National Vision $50M renewed), debt reductions (e.g., Republic $231.6M repaid), and dividends maintained/raised (e.g., Global Water $0.30396 annualized), signaling management conviction amid 15 guidance issuances mostly maintained/raised for 2026. Insider activity is sparse but positive where noted (e.g., no major sales); M&A/divestitures active in 12 filings (e.g., Ziff Davis sale to Accenture, Diversified Energy $245M acquisition). Critical developments: 2 bankruptcies/delistings (Charles & Colvard Ch11, Vicarious NYSE delisting), but portfolio-level trends show improving cash flows (15/25 with data up YoY) and backlog growth (e.g., Orion +470% implied via Babcock). Implications: Rotate to growth sectors like healthcare/tech (avg +12% revenue) from retail; monitor Q1 2026 catalysts for alpha.

65 high priority 56 medium 121 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 04, 2026

Across 69 filings from S&P 500 Consumer Discretionary and adjacent sectors, overarching themes include mixed revenue growth with top-line expansion in 7/15 retail/fitness firms (avg +10% YoY, e.g., Black Rock Coffee +24.5%, Abercrombie +6%) offset by widespread margin compression (avg -150bps across 9 reporters) and operational losses; capital returns remain robust with buybacks/dividends in 8 firms (e.g., Abercrombie $450M repurchase, Brown-Forman $400M). M&A/divestitures active (Ziff Davis sale to Accenture, Farmer Bros acquisition at $1.29/share), alongside leadership transitions signaling AI/strategic pivots (FactSet AI officers). Period-over-period trends show YoY revenue growth in 12/25 quantified filers (+avg 8%) but net income declines in 10/20 (-avg 25%), with forward guidance cautious (e.g., Abercrombie 3-5% sales growth FY26). Portfolio-level patterns flag consumer resilience in apparel/restaurants but vulnerability in fitness/specialty retail amid cost pressures; actionable now: prioritize buyback-heavy names pre-AGMs.

38 high priority 31 medium 69 total filings